Spanyol - Spanyol - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

bela-pharm gmbh & co. kg - lidocaina hidrocloruro - soluciÓn inyectable - lidocaina hidrocloruro 20 - lidocaína - caballos; perros; gatos

Uni Eropa - Spanyol - EMA (European Medicines Agency)

ultragenyx germany gmbh - vestronidase alfa - la mucopolisacaridosis de tipo vii - las enzimas - mepsevii está indicado para el tratamiento de la no-manifestaciones neurológicas de la mucopolisacaridosis de tipo vii (mps vii; síndrome de sly).

Uni Eropa - Spanyol - EMA (European Medicines Agency)

biontech manufacturing gmbh - single-stranded, 5’-capped messenger rna produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - vacunas - comirnaty 30 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty original/omicron ba. 1 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older who have previously received at least a primary vaccination course against covid-19. comirnaty original/omicron ba. 4-5 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty original/omicron ba. 4-5 (1. 5/1. 5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty omicron xbb. 5 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty omicron xbb. 5 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 10 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. el uso de esta vacuna debe estar en conformidad con las recomendaciones oficiales.

Uni Eropa - Spanyol - EMA (European Medicines Agency)

roche registration gmbh - pertuzumab, trastuzumab - neoplasias de la mama - agentes antineoplásicos - early breast cancer (ebc)phesgo is indicated for use in combination with chemotherapy in:the neoadjuvant treatment of adult patients with her2-positive, locally advanced, inflammatory, or early stage breast cancer at high risk of recurrencethe adjuvant treatment of adult patients with her2-positive early breast cancer at high risk of recurrencemetastatic breast cancer (mbc)phesgo is indicated for use in combination with docetaxel in adult patients with her2-positive metastatic or locally recurrent unresectable breast cancer, who have not received previous anti-her2 therapy or chemotherapy for their metastatic disease.

Uni Eropa - Spanyol - EMA (European Medicines Agency)

roche registration gmbh - faricimab - wet macular degeneration; macular edema; diabetes complications - oftalmológicos - vabysmo is indicated for the treatment of adult patients with:neovascular (wet) age-related macular degeneration (namd),visual impairment due to diabetic macular oedema (dme).

Uni Eropa - Spanyol - EMA (European Medicines Agency)

fresenius kabi deutschland gmbh - tocilizumab - arthritis, rheumatoid; cytokine release syndrome; arthritis, juvenile rheumatoid; covid-19 virus infection; giant cell arteritis - inmunosupresores - tyenne, in combination with methotrexate (mtx), is indicated for- the treatment of severe, active and progressive rheumatoid arthritis (ra) in adults not previously treated with mtx. - the treatment of moderate to severe active ra in adult patients who have either responded inadequately to, or who were intolerant to, previous therapy with one or more disease-modifying anti-rheumatic drugs (dmards) or tumour necrosis factor (tnf) antagonists. in these patients, tyenne can be given as monotherapy in case of intolerance to mtx or where continued treatment with mtx is inappropriate. tocilizumab has been shown to reduce the rate of progression of joint damage as measured by x-ray and to improve physical function when given in combination with methotrexate. tyenne is indicated for the treatment of coronavirus disease 2019 (covid-19) in adults who are receiving systemic corticosteroids and require supplemental oxygen or mechanical ventilation. tyenne is indicated for the treatment of active systemic juvenile idiopathic arthritis (sjia) in patients 1 year of age and older, who have responded inadequately to previous therapy with nsaids and systemic corticosteroids. tyenne can be given as monotherapy (in case of intolerance to mtx or where treatment with mtx is inappropriate) or in combination with mtx. tyenne in combination with methotrexate (mtx) is indicated for the treatment of juvenile idiopathic polyarthritis (pjia; rheumatoid factor positive or negative and extended oligoarthritis) in patients 2 years of age and older, who have responded inadequately to previous therapy with mtx. tyenne can be given as monotherapy in case of intolerance to mtx or where continued treatment with mtx is inappropriate. tyenne is indicated for the treatment of chimeric antigen receptor (car) t cell-induced severe or life-threatening cytokine release syndrome (crs) in adults and paediatric patients 2 years of age and older. tyenne is indicated for the treatment of giant cell arteritis (gca) in adult patients.

Uni Eropa - Spanyol - EMA (European Medicines Agency)

roche registration gmbh - obinutuzumab - leucemia, linfocítica, crónica, b-cell - agentes antineoplásicos - leucemia linfocítica crónica (llc)gazyvaro en combinación con clorambucilo está indicado para el tratamiento de pacientes adultos no tratados previamente con leucemia linfocítica crónica (cll) y con comorbilidades que los hace inadecuados para la dosis completa de fludarabina basado en la terapia (véase la sección 5. el linfoma folicular (fl)gazyvaro en combinación con la quimioterapia, seguido de gazyvaro la terapia de mantenimiento en pacientes que lograron una respuesta, está indicado para el tratamiento de los pacientes no tratados previamente con linfoma folicular avanzado. gazyvaro en combinación con bendamustina seguido por gazyvaro de mantenimiento está indicado para el tratamiento de pacientes con linfoma folicular (fl) que no responden o que progresó durante o hasta 6 meses después del tratamiento con rituximab o rituximab-que contiene el régimen.

Uni Eropa - Spanyol - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - eprinomectin, fipronil, praziquantel, (s) -methoprene - antiparasitic products, insecticides and repellents, avermectins, eprinomectin, combinations, - gatos - para gatos con, o en riesgo de infestaciones mixtas por cestodos, nematodos y ectoparásitos. el medicamento veterinario es exclusivamente indicado cuando los tres grupos son dirigidos en el mismo tiempo. ectoparasitestreatment y la prevención de infestaciones por pulgas (ctenocephalides felis). la eliminación de las pulgas en 24 horas. un tratamiento previene futuras infestaciones por lo menos un mes. de prevención ambiental de pulgas de la contaminación mediante la inhibición del desarrollo de la pulga de los estados inmaduros (huevos, larvas y pupas) durante más de un mes. el producto puede usarse como parte de una estrategia de tratamiento para el control de la dermatitis alérgica a las pulgas (fad). tratamiento y prevención de infestaciones por garrapatas (ixodes ricinus). la eliminación de las garrapatas en 48 horas. un tratamiento previene futuras infestaciones por hasta 3 semanas. tratamiento de notoedric de la sarna (notoedres cati). cestodestreatment de infestaciones con las tenias (dipylidium caninum, taenia taeniaeformis, echinococcus multilocularis, joyeuxiella pasqualei (adulto), y joyeuxiella fuhrmanni (adulto)). nematodestreatment de infestaciones con nematodos gastrointestinales (l3, l4 adultos y larvas de toxocara cati, los adultos de toxascaris leonina, l4 adultos y larvas de ancylostoma tubaeforme y ancylostoma ceylanicum, y los adultos de ancylostoma brazilienze). tratamiento de infestaciones con felino lombrices pulmonares (larvas l3, l4 larvas y adultos de aelurostrongylus abstrusus, l4 larvas y adultos de troglostrongylus brevior). tratamiento de infestaciones con vesical gusanos (capillaria plica). prevención de la enfermedad del gusano del corazón (dirofilaria immitis larvas) por un mes.

Uni Eropa - Spanyol - EMA (European Medicines Agency)

elanco gmbh - benazepril hydrochloride, pimobendan - inhibidores ace, combinaciones - perros - para el tratamiento de la insuficiencia cardíaca congestiva por insuficiencia valvular auriculoventricular o miocardiopatía dilatada en perros.

Uni Eropa - Spanyol - EMA (European Medicines Agency)

elanco gmbh - pegbovigrastim - factores estimulantes de colonias, inmunoestimulantes, agentes antineoplásicos - cattle (cows and heifers); cattle - como ayuda en un programa de manejo de rebaños, para reducir el riesgo de mastitis clínica en vacas lecheras y novillas periparturientas durante los 30 días posteriores al parto.